miR-17-92 Cluster |
Bim (3, 4) |
Participate in B-cell proliferation and cell-death control (3, 4) |
|
|
Pten (4) |
|
|
miR-24 |
Bim and Caspase 9 (5) |
Inhibit B-cell development, under the control of PU.1 (5, 6) |
|
miR-29a |
TCL1, MCL10, and CDK6 (7) |
|
Up-regulated in indolent B-cell chronic lymphocytic leukemia (CLL) compared to normal B cells (8). |
miR-34a |
Foxp1 (9) |
Induces block of B-cell development whereas its deletion induces high number of mature B cells (9) |
|
miR-146a |
Irak1 and Traf6 (10) |
Participate in B-cell development, over-expression causes spontaneous autoimmune disorders in mice (10, 11) |
Over-expressed in patients suffering from rheumatoid arthritis and psoriasis (12–14) |
|
Fas (11). |
|
Over-expressed in kidney biopsy and urine from patients with IgA nephropathy (15) |
|
|
|
Induced by EBV and inhibits the expression of interferon related genes (16) |
miR-150 |
c-Myb (17). |
Its over-expression in B-cell progenitors results in a partial block of B-cell development and a reduction in B1-cell numbers (17). |
Under-expressed in peripheral B cells from SLE patients (18) |
miR-155 |
Pu.1 (Sfpi1 gene) (19) |
Reduced generation of high-affinity antibodies against a T-cell-dependent antigen (19, 20) |
Over-expressed in peripheral B cells from SLE patients (18) |
|
Shp1 (21) |
|
Is induced by EBV, through LMP1 and: |
|
Aid (20, 22) |
|
-targets BMP signaling cascade suggesting an inhibition of the antitumor effects of BMP signaling (23) |
|
|
|
-contributes to the resistance toward Rituximab in inducing cell survival signal (24) |
miR-181a |
Bim (25) |
Its over-expression inhibits the pro-apoptotic protein BIM (25) and increases number of B-lineage cells (26) |
|
miR-181b |
Aid (27) |
Impairs the class-switch recombination (27) |
|
miR-210 |
|
Control of immunoglobin class-switch and under the control of Oct-2 (28) |
|
miR-221 |
|
Implicated in the retention of early B-lineage cells in bone marrow and under the control of PAX5 (29). |
|